- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01690442
HIV Prevention for Injecting Drug Users in Kazakhstan
February 25, 2014 updated by: Nabila El-Bassel, PhD, Columbia University
Couples Based HIV/STI Prevention for Injecting Drug Users in Kazakhstan
The proposed study addresses a significant public health threat of HIV, HCV and other STIs among a very high risk population of active IDUs and their sexual partners in Kazakhstan a region that is experiencing one of the fastest rising HIV epidemics in the world.
There is a race to develop and implement effective HIV preventive interventions for IDUs and their sexual partners to stem the spread of HIV, HCV and other STIs in Almaty, Shu and other Central Asian towns along drug trafficking routes.
The proposed study will test the effectiveness of a couplesbased HIV/STI risk reduction intervention to decrease new cases of HIV and Hepatitis C (HCV) and incidence of sexually transmitted infections (STIs), as well as to reduce unsafe injection practices and increase condom use among injecting drug users (IDUs) and their heterosexual, intimate partners in Kazakhstan.
Study Overview
Status
Completed
Detailed Description
The proposed study will rigorously test the efficacy of an innovative, couplesbased HIV/STI risk reduction intervention to decrease new cases of HIV and Hepatitis C (HCV) and incidence of sexually transmitted infections (STIs), as well as to reduce unsafe injection practices and increase condom use among injecting drug users (IDUs) and their heterosexual intimate partners in Kazakhstan.
Central Asia has experienced one of the fastest growing HIV/AIDS epidemics due to a sharp increase in injection drug use.
For the proposed study, the participants will be 400 IDUs and their heterosexual intimate partners.
These 400 couples will be randomized to one of two interventions: a 5session couplesbased HIV/STI risk reduction intervention or a 5session couplesbased wellness promotion intervention, which will serve as a control condition.
Participants will be assessed with repeated measures at baseline, 3, 6, and 12months postintervention.
The primary behavioral outcomes are selfreported proportion of injection acts in which needles or syringes are shared in the past 90 days and proportion of condom protected acts of sexual intercourse in the past 90 days.
The primary biological outcomes are the rate of new HIV and HCV cases, and the cumulative incidence of Chlamydia, gonorrhea, and syphilis over the 12month postintervention period.
The proposed study will advance the understanding of HIV/HCV/STI risk reduction among IDUs and thereby may help to stem the rising epidemic of HIV, HCV, and STIs in Kazakhstan and Central Asia.
Study Type
Interventional
Enrollment (Actual)
600
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Almaty, Kazakhstan
- Global Health Research Center of Central Asia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Couples are eligible to participate if both partners are aged 18 or older
- both partners identify each other as their main partner of the opposite sex and someone whom the participant considers a boy/girlfriend, spouse, lover and/ or parent of his/her child
- the relationship has existed at least 3 months
- each partner intends to remain together for at least 12 months
- at least one partner reports having had unprotected vaginal or anal intercourse with the other partner at least once in the previous 90 days
- at least one partner reports injecting drugs in the past 90 days
- neither partner has plans to relocate beyond a reasonable distance from the study site
Exclusion Criteria:
- Couples are excluded if either partner shows evidence of significant psychiatric, physical or neurological impairment that would limit effective participation as confirmed on a MiniMental State Examination and/or Quick Test
- either partner reports severe physical violence perpetrated by the other partner in the past year on the Revised Conflict Tactics Scale
- either partner is unable to commit to participate in the study through to completion
- either partner reports that the couple is planning a pregnancy within the next 18 months
- either partner is not fluent in Russian as determined during Informed Consent
- both partners do not meet all eligibility criteria or meet one or more exclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Couples Based HIV/STI Risk Reduction Intervention (CHSR)
The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
|
The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
|
|
Active Comparator: Renaissance Wellness Promotion (WP)
This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
|
This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The proportion of condom protected acts of vaginal and anal intercourse
Time Frame: 12 months
|
12 months
|
|
The number of incidents of unclean syringes or needles in the past 90 days
Time Frame: 12 months
|
12 months
|
|
Proportion of injection acts in which unclean needles or syringes were used in the past 90 days
Time Frame: 12 months
|
12 months
|
|
The number of acts of unprotected vaginal and anal intercourse during the 90 days prior to the assessment period
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of people participants shared needles or syringes with in the past 90 days
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nabila El-Bassel, Columbia University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2008
Primary Completion (Actual)
November 1, 2012
Study Completion (Actual)
November 1, 2012
Study Registration Dates
First Submitted
September 19, 2012
First Submitted That Met QC Criteria
September 19, 2012
First Posted (Estimate)
September 21, 2012
Study Record Updates
Last Update Posted (Estimate)
February 27, 2014
Last Update Submitted That Met QC Criteria
February 25, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- AAAD2056
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
Duke UniversityGilead SciencesRecruitingHIV Prevention | HIV Pre-exposure Prophylaxis | HIV Prevention Program | HIV Prevention and Care | HIV Pre-exposure Prophylaxis UseUnited States
-
Federal University of São PauloGilead SciencesCompleted
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)RecruitingPrEP | HIV | HIV Prevention | PrEP UptakeUnited States
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH)RecruitingHIV Prevention | PrEP Adherence | HIV Related StigmaThailand
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RecruitingFeasibility | HIV Prevention | PrEP Uptake | Acceptability | HIV Self-testing | Male Partners of HIV-negative Postpartum WomenSouth Africa
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of PennsylvaniaNational Institute of Mental Health (NIMH); University of BotswanaRecruitingPregnancy | HIV | Post-partum | HIV Antiretroviral Therapy (ART) AdherenceBotswana
Clinical Trials on Couples Based HIV/STI Risk Reduction Intervention (CHSR)
-
University of PennsylvaniaNational Institute on Minority Health and Health Disparities (NIMHD)CompletedHuman Immunodeficiency Virus (HIV) | Sexually Transmitted Disease (STD)United States
-
University of ConnecticutCompletedSexually Transmitted InfectionsUnited States
-
Women and Infants Hospital of Rhode IslandUniversity of Rhode IslandCompletedSubstance-Related Disorders | Sexually Transmitted DiseasesUnited States
-
Emory UniversityAmerican University of ArmeniaCompletedHIV Infections | HIV PreventionArmenia
-
Columbia UniversityCompletedSexually Transmitted InfectionsUnited States
-
Michele StatonNational Institute on Drug Abuse (NIDA)CompletedHepatitis C | Drug Abuse | Acquired Immune Deficiency Syndrome VirusUnited States
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)CompletedHIV Infections | Sexually Transmitted DiseasesUnited States
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)CompletedSexually Transmitted Disease (STD) | Human Immunodeficiency Virus Infection (HIV)United States
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaboratorsCompleted
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Indian Council of Medical Research and other collaboratorsCompletedHIV Infection | Sexual Behavior | Health BehaviorUnited States, India